Charles Schwab Investment Management Inc. Acquires 134,815 Shares of Bristol-Myers Squibb (NYSE:BMY)

Charles Schwab Investment Management Inc. raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,361,717 shares of the biopharmaceutical company’s stock after buying an additional 134,815 shares during the period. Charles Schwab Investment Management Inc. owned 0.56% of Bristol-Myers Squibb worth $582,970,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. OFI Invest Asset Management bought a new position in shares of Bristol-Myers Squibb in the third quarter valued at approximately $25,000. Milestone Investment Advisors LLC bought a new stake in Bristol-Myers Squibb during the third quarter valued at about $27,000. Blue Bell Private Wealth Management LLC grew its position in shares of Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares during the last quarter. Turtle Creek Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $40,000. Finally, Wetzel Investment Advisors Inc. acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $40,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

NYSE:BMY traded up $0.14 during mid-day trading on Tuesday, reaching $44.04. The stock had a trading volume of 10,924,172 shares, compared to its average volume of 15,784,603. The stock has a 50-day simple moving average of $50.11 and a two-hundred day simple moving average of $50.48. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. Bristol-Myers Squibb has a 12 month low of $43.33 and a 12 month high of $69.10. The stock has a market capitalization of $89.27 billion, a PE ratio of -14.21, a P/E/G ratio of 14.82 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter in the previous year, the company posted $2.05 EPS. Bristol-Myers Squibb’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were paid a $0.60 dividend. The ex-dividend date was Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.45%. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on BMY shares. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. BMO Capital Markets reduced their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Barclays lowered their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Finally, Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.